Categories

I-CARE Early Covid (3) I-CARE Flu and RSV (1) I-PREVENT (28) I-RECOVER Long Covid (3) I-RECOVER Post-Vaccine (3) MATH+ (20)

Tags

25-hydroxyvitamin D (2) 25‐HYDROXY VITAMIN D (2) Ambulatory treatment (2) Anti-inflammatory (2) Anti-Inflammatory Agents (1) Anticoagulant (2) Antimicrobial Cationic Peptides (1) Antiparasitic Agents (3) Antiviral (2) Ascorbic Acid (3) Calcifediol (1) Collagen (1) Coronavirus (2) COVID-19 (23) Dithiothreitol (1) Endothelial Barrier (1) Endothelial Permeability (1) Epidemiology (2) Ergocalciferols (1) Famotidine (7) Fixed drug eruption (1) Glucocorticosteroids (3) Heparanase (2) Human immunodeficiency virus (HIV) (1) Hydroxychloroquine (2) Inflammation (4) ivermectin (18) Melatonin (13) Methylprednisol (2) Nitric Oxide (1) Omicron (6) Onchocerciasis (1) pharmacokinetics (1) Pneumonia (2) SARS-CoV-2 (20) Sars-CoV2 (2) Sepsis (3) Septic (2) Spike Protein (5) Stevens–Johnson syndrome (SJS) (1) Tempol (1) viral infection (3) Vitamin C (3) Vitamin D (6) vitamin D 2 (1)

  • Reference: Early outpatient treatment of symptomatic, High-Risk Covid-19 patients that should be rampedup immediately as key to the pandemic crisis

    Published On: November 2, 2020

    More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it.

    Categories:

    Tags: azithromycin, Coronavirus, COVID-19, doxycycline, Hydroxychloroquine, SARS-CoV-2, Zinc